NCT07703774

Brief Summary

This study will provide novel insights into the role of bone marrow-derived stem cells in muscle adaptation to long-term exercise and advance our understanding of an Rg-1 based supplement-Senactiv® as a potential intervention for preventing sarcopenia and cognitive decline in older adults.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
29mo left

Started Aug 2026

Typical duration for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 9, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 14, 2026

Completed
19 days until next milestone

Study Start

First participant enrolled

August 2, 2026

Expected
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 2, 2029

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 2, 2029

Last Updated

July 22, 2026

Status Verified

July 1, 2026

Enrollment Period

2.4 years

First QC Date

July 9, 2026

Last Update Submit

July 20, 2026

Conditions

Myeloid Cell Infiltration

Keywords

Nestin+ cellsNeural stem cellsAcetylcholine receptor

Outcome Measures

Primary Outcomes (1)

  • Bone marrow derived cells in skeletal muscle

    Cell markers with bone marrow identity

    * 3 weeks before exercise (baseline) * Immediately after exercise (0 hour) * 1-hour after exercise (1 h) * 24-hour after exercise (24 h)

Study Arms (2)

Placebo

PLACEBO COMPARATOR
Behavioral: Resistance exercise

Senactiv

EXPERIMENTAL

Rg1-based supplement

Behavioral: Resistance exercise

Interventions

Resistance exerciseBEHAVIORAL

4 sets of 8-RM leg squats

PlaceboSenactiv

Eligibility Criteria

Age20 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- Must be able to swallow pills

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Resistance Training

Intervention Hierarchy (Ancestors)

Exercise TherapyRehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsPhysical Therapy ModalitiesPhysical Conditioning, HumanExerciseMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Central Study Contacts

Chia-Hua Kuo, PhD

CONTACT

+85263057921kuochiahua@gmail.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Masking Details
Care providers will administer either the placebo or the treatment to participants without knowledge of the pill centent allocation. The placebo and treatment pills will be manufactured to be indistinguishable in appearance, ensuring blinding of both care providers and participants.
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Randomized controlled trial of Rg1 and Placebo supplementation
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 9, 2026

First Posted

July 14, 2026

Study Start (Estimated)

August 2, 2026

Primary Completion (Estimated)

January 2, 2029

Study Completion (Estimated)

January 2, 2029

Last Updated

July 22, 2026

Record last verified: 2026-07